Annie Delaunois

7PUBLICATIONS
17CO-AUTHORS
Toxicology (incl. clinical toxicology)Molecular medicinePharmacogenomicsVeterinary diagnosis and diagnosticsCommercial law
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 08, 2024
Assessing the interplay between off-target promiscuity, cytotoxicity, and tolerability in rodents to improve the safety profile of novel anti-malarial plasmepsin X inhibitors.

Helga H J Gerets, Annie Delaunois, Alvaro Cardenas

|Jul 08, 2024
Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials.

Annie Delaunois, Alvaro Cardenas, Teresa de Haro

|Jun 17, 2024
Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines.

Richard J Brennan, Stephen Jenkinson, Andrew Brown

|May 21, 2024
The state of the art in secondary pharmacology and its impact on the safety of new medicines.

Richard J Brennan, Stephen Jenkinson, Andrew Brown

|May 06, 2024
Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices.

Anne-Marie Bétat, Annie Delaunois, Eric Delpy

|Feb 07, 2023
Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case study.

Annie Delaunois, François-Xavier Mathy, Miranda Cornet

Pageof 2